Profile

Syntab Therapeutics is a focused, private German biotechnology company developing a proprietary class of chemically synthesized bispecific molecules called Innate Immune System Engagers (ISErs, "Macrophage Engagers"). Syntab’s technology platform offers a new path in the cancer therapy space and is expected to exhibit excellent selectivity for a range of cancer-relevant targets. The company established a lean management for its development in tight collaboration with selective and excellent academic partners in Vienna and Aachen University Hospital for preclinical studies. The company has its registered office in Aachen, North Rhine-Westphalia.